Rapid pathogen identification and phenotypic antimicrobial susceptibility directly from urine specimens.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 11 2022
15 11 2022
Historique:
received:
22
07
2022
accepted:
19
10
2022
entrez:
15
11
2022
pubmed:
16
11
2022
medline:
19
11
2022
Statut:
epublish
Résumé
Implementing effective antimicrobial therapy close to the onset of infection lowers morbidity and mortality and attenuates the spread of antimicrobial resistance. Current antimicrobial susceptibility testing (AST) methods, however, require several days to determine optimal therapies. We present technology and an automated platform that identify (ID) Urinary Tract Infection pathogens in 45 min and provide phenotypic AST results in less than 5 h from urine specimens without colony isolation. The ID and AST tests count cells fluorescently labeled with specific rRNA probes using non-magnified digital imaging. The ID test detected five pathogens at ≤ 7,000 CFU/mL and had a linear range of ~ 4 orders of magnitude. For contrived specimens, AST tests gave 93.1% categorical agreement with 1.3% Very Major Errors (VME), 0.3% Major Errors (ME), and 6.3% minor Errors (mE) compared to the broth microdilution (BMD) reference method. For clinical specimens, the ID test had 98.6% agreement and the AST test had 92.3% categorical agreement with 4.2% mE, 3.4% ME and 4.0% VME compared to BMD. Data presented demonstrates that direct-from-specimen AST tests can accurately determine antimicrobial susceptibility/resistance for each pathogen in a specimen containing two pathogens. The method is robust to urine matrix effects and off-target commensal and contaminating bacteria.
Identifiants
pubmed: 36380053
doi: 10.1038/s41598-022-22792-y
pii: 10.1038/s41598-022-22792-y
pmc: PMC9666529
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18315Subventions
Organisme : NIAID NIH HHS
ID : R44 AI157672
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : 1R01AI117058-01
Organisme : U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (BARDA)
ID : #HHSO100201500022C
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : >1R44AI157672-01
Informations de copyright
© 2022. The Author(s).
Références
Nat Rev Microbiol. 2015 May;13(5):269-84
pubmed: 25853778
Sci Rep. 2018 May 30;8(1):8364
pubmed: 29849171
Clin Microbiol Infect. 2017 Jan;23(1):2-22
pubmed: 27890457
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301
pubmed: 27573805
Lancet Infect Dis. 2012 Dec;12(12):919-24
pubmed: 23103175
Int Urol Nephrol. 2020 Mar;52(3):431-436
pubmed: 31691136
PLoS One. 2022 Feb 16;17(2):e0263868
pubmed: 35171945
BJOG. 2020 Jan;127(2):193-201
pubmed: 31469215
Antibiotics (Basel). 2021 Feb 20;10(2):
pubmed: 33672677
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Antibiotics (Basel). 2022 Mar 23;11(4):
pubmed: 35453179
Nat Rev Microbiol. 2020 May;18(5):299-311
pubmed: 32055026
Adv Sci (Weinh). 2021 Feb 01;8(6):2003419
pubmed: 33747737
Eur Urol Focus. 2019 Jan;5(1):5-9
pubmed: 30448051
Nat Rev Urol. 2017 May;14(5):296-310
pubmed: 28248946
Clin Infect Dis. 2022 Apr 9;74(7):1284-1292
pubmed: 34463708
Clin Lab Med. 2019 Sep;39(3):333-344
pubmed: 31383260